V940 added to adjuvant pembrolizumab improved distant metastasis-free survival and showed a trend toward prolonged progression-free survival without introducing new safety signals, with adverse events mainly consisting of flu-like symptoms [ 72 ].
← all excerpts
After a Decade of Therapy Revolution in Cutaneous Melanoma-Perspectives on Emerging Treatment Strategies.
1
—
—